knowledge -WSS

knowledge

author：fashion 2025-10-03 01:05:14 - browse：95653

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Gene therapy denied for Afghan refugee whose father aided U.S.

WSS

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Physician assistants need a new name. Here's what it should be

A preacher's new calling: Diversifying neuroscience research

Boston Scientific acquires urology company Axonics for $3.7 billion

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Congress needs to close a vaccine

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Psychedelics group wrestles with new pharma identity

Elevance PBM president out as customers face prescription chaos

DIEP, the 'gold standard' of breast reconstruction, is under threat

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

What does generative AI mean for health care? We asked experts

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Affirmative action in medical school literally saved lives

Fight over Supreme Court dialysis ruling puts kidney patients at risk

explore

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Medicare Advantage overpayments discussion gets experts fired up

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Finland to offer bird flu vaccine to select groups of people, a possible global first

A new initiative will help leaders fight the next pandemic

Anthony Fauci pushes back on GOP claims during Covid hearing

knowledge

knowledge

focus

hotspot